NCT05335356 - Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

384

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

January 26, 2023

Study Completion Date

November 15, 2023

Conditions

Moderate to Severe Chronic Plaque Psoriasis

Interventions

BIOLOGICAL

Stelara

45 mg , 90 mg at Week 0, 4, 16, 28 and 40;During the study after receiving 2 doses , before dosing at Week 16 patients were re-randomised in a 1:1 ratio to receive either Bmab 1200 or Stelara .

BIOLOGICAL

Bmab1200

45 mg , 90 mg at Week 0, 4, 16, 28 and 40

Trial Locations (1)

44124

Apex Clinical Research Center, Mayfield Heights